Among the HR‐negative patients, significant differences in age, menopause status, histological grade, Ki67, AR status, TOPIIa, and surgical modality were found between the HER2‐low and HER2‐0 BC patient groups (p < 0.05; Table 2). This evidence concerns the gene ERBB2 and breast cancer.